Autifony is focused on the development of high value, novel medicines to treat serious diseases of the central nervous system.
The company was founded in 2011 as a spin-out from GlaxoSmithKline by Charles Large and Giuseppe Alvaro, previously Directors in GSK's Neuroscience Centre of Excellence for Drug Discovery. Autifony is backed by Touchstone Innovations, SV Life Sciences, Pfizer Venture Investments, International Biotechnology Trust PLC and UCL Business.
Autifony’s lead product AUT00063 is currently in a Phase IIa trial for age-related hearing loss. This is a very common problem for which the only (poor) solution is currently hearing aids – no pharmacological treatments currently exist. Age-related hearing affects up to half of people over the age of 65.